Pancreatic Cancer Reagents

Home > Featured Products > Oncology Research > Pancreatic Cancer

Prostate cancer is the most common non-skin cancer in men. Biomarker-driven research — from PSA-based screening to PSMA-targeted theranostics — is transforming diagnosis and treatment. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO

Key Biomarkers & Targets

PSA / KLK3

Prostate-Specific Antigen

The most widely used prostate cancer screening biomarker. 27 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

PSMA

FOLH1 / GCPII

Overexpressed in prostate cancer; therapeutic and imaging target (lutetium-177 PSMA). 49 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

Androgen Receptor

Central driver of prostate cancer; target of enzalutamide, abiraterone. 75 products. Validated: Blocking, ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

ERG

ETS Transcription Factor

TMPRSS2-ERG fusion in ~50% of prostate cancers. IHC surrogate marker. 14 products. Validated: ELISA, IHC, WB.

Antibodies • Proteins

TMPRSS2

Transmembrane Serine Protease

Fusion partner in TMPRSS2-ERG rearrangement. 13 products. Validated: ELISA, IHC, WB.

Antibodies • Proteins

STEAP

Six-Transmembrane Protein

Emerging ADC target with prostate cancer specificity. 16 products. Validated: Blocking, ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

PD-L1

CD274

Checkpoint target for immunotherapy stratification. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

PTEN

Tumor Suppressor

PTEN loss associated with aggressive disease and PI3K/AKT activation. 6 products. Validated: ELISA, IHC, WB.

Antibodies • Proteins

Why Researchers Choose abinScience

IHC-Validated AntibodiesAntibodies with IHC validation available for: PSA, PSMA, AR, ERG, TMPRSS2, STEAP. See individual product pages for clone details and recommended dilutions.

Flow Cytometry ReadyFC-validated antibodies available for: PSA, PSMA, AR, STEAP, PD-L1. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.

Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: PSA, PSMA, AR, STEAP, PD-L1.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

IHC-based biomarker detection: We offer IHC-validated antibodies for PSA, PSMA, AR, ERG, TMPRSS2. See product pages for validated species and recommended dilutions.
Flow cytometry immunophenotyping: FC-validated antibodies available for PSA, PSMA, AR, STEAP, PD-L1. Select clones offered in FITC, APC, PE, and PerCP conjugates.
Functional and blocking assays: Antibodies with blocking/neutralization validation available for: PSA, PSMA, AR, STEAP.
Biosimilar comparability: Research-grade biosimilar proteins (ELISA/FACS/Functional assay validated) available for PSA, PSMA, AR, STEAP.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What PD-L1 reagents do you offer?

We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).

What AR reagents do you offer?

We offer 60 detection antibodies, 9 research-grade biosimilar proteins, and 6 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), N430/20 (IHC, WB; unconjugated), N430/26 (IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Avdoralimab, CD88/C5AR1 (ADC-1004), CD88/C5AR1 (MOR210)).

What PSMA reagents do you offer?

We offer 22 detection antibodies, 14 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A097 (ELISA, IHC, WB; unconjugated), 1A098 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Pasotuxizumab, HuJ591-Gsmab, Rosopatamab).

What PSA / KLK3 reagents do you offer?

We offer 23 detection antibodies, 2 research-grade biosimilar proteins, and 2 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A553 (ELISA, IHC, WB; unconjugated), 1A554 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Lanadelumab, Navenibart).

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.